A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant | Zendy

Claire Horgan | Zendy; Alexandros Kanellopoulos | Zendy; Shankara Paneesha | Zendy; Bhuvan Kishore | Zendy; Richard Lovell | Zendy; Emmanouil Nikolousis | Zendy

Open Access

A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant

Author(s) -

Claire Horgan,

Alexandros Kanellopoulos,

Shankara Paneesha,

Bhuvan Kishore,

Richard Lovell,

Emmanouil Nikolousis

Publication year - 2019

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2019.7800

Subject(s) - medicine , azacitidine , myeloid leukemia , complete remission , salvage therapy , refractory (planetary science) , oncology , stem cell , donor lymphocyte infusion , transplantation , hematopoietic stem cell transplantation , chemotherapy , biochemistry , gene expression , chemistry , physics , genetics , astrobiology , biology , dna methylation , gene

A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced intensity HLAA mismatch Campath conditioning allogeneic stem cell transplant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research